重症监护药学服务立场声明(执行摘要):2020年更新
美国重症医学会、美国临床药学学院重症实践与研究网络、美国卫生系统药师协会联合召集15名药师组成工作组,采用改良德尔菲法(共识阈值>66%)制定推荐。最终形成82条推荐:44条原始推荐、38条新推荐;按ICU服务层级分类,覆盖患者照护(34条)、质量改进(21条)、研究与学术(9条)、培训与教育(10条)、职业发展(8条)五个领域。声明界定重症监护药师的活动与ICU内药学服务范围,结论呼吁所有利益相关方努力实施推荐并持续改进重症患者照护。
要点
- 82条推荐中44条为原始推荐、38条为新推荐,按ICU服务层级分类以适用于不同设置。
- 患者照护领域34条推荐,主要涉及重症监护药师职责与药学服务。
- 质量改进领域21条推荐,涉及患者在用药安全、临床质量项目和分析中的药师角色。
- 研究与学术9条、培训与教育10条、职业发展8条推荐。
- 共识采用改良德尔菲法,每个实践推荐达到>66%同意方为达成共识。
适用人群与场景
- ICU场景中的重症监护药师及药学服务,推荐按ICU服务层级分类以适用于不同设置。
处置流程与药物剂量
- 采用改良德尔菲法,每个实践推荐需达到>66%同意方为共识。
- 既往立场声明推荐经审阅并投票决定保留、修订或废止。
- 推荐按ICU服务层级分类,并归入患者照护、质量改进、研究与学术、培训与教育、职业发展五个领域。
研究设计与关键结果
- 多组织联合工作组由15名药师组成,代表重症药学实践与药学管理的广泛截面,涵盖地域、重症实践设置和角色。
- 共82条推荐:44条原始推荐、38条新推荐;患者照护34条、质量改进21条、研究与学术9条、培训与教育10条、职业发展8条。
证据类型、等级与局限
- 证据类型:多组织立场声明(执行摘要),由美国重症医学会、美国临床药学学院重症实践与研究网络、美国卫生系统药师协会联合工作组制定。
- 共识方法:改良德尔菲法,共识阈值为>66%同意。
- 局限:原文未报告局限性
对床旁实践的改变
- 声明界定的推荐描述重症监护药师的活动与ICU内药学服务范围,供各ICU按服务层级参照实施。
- 作者结论认为所有利益相关方应努力实施所提供推荐,并持续改进重症患者照护。
指南或共识出处
- Position Paper on Critical Care Pharmacy Services (Executive Summary): 2020 Update,美国重症医学会、美国临床药学学院重症实践与研究网络、美国卫生系统药师协会,2020年。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Provide a multiorganizational statement to update the statement from a paper in 2000 about critical care pharmacy practice and makes recommendations for future practice.
DESIGN: The Society of Critical Care Medicine, American College of Clinical Pharmacy Critical Care Practice and Research Network, and the American Society of Health-Systems Pharmacists convened a joint task force of 15 pharmacists representing a broad cross-section of critical care pharmacy practice and pharmacy administration, inclusive of geography, critical care practice setting, and roles. The Task Force chairs reviewed and organized primary literature, outlined topic domains, and prepared the methodology for group review and consensus. A modified Delphi method was used until consensus (> 66% agreement) was reached for each practice recommendation. Previous position statement recommendations were reviewed and voted to either retain, revise, or retire. Recommendations were categorized by level of ICU service to be applicable by setting, and grouped into five domains: patient care, quality improvement, research and scholarship, training and education, and professional development.
MAIN RESULTS: There are 82 recommendation statements: forty-four original recommendations and 38 new recommendation statements. Thirty-four recommendations were made for patient care, primarily relating to critical care pharmacist duties and pharmacy services. In the quality improvement domain, 21 recommendations address the role of the critical care pharmacist in patient and medication safety, clinical quality programs, and analytics. Nine recommendations were made in the domain of research and scholarship. Ten recommendations are in the domain of training and education and eight recommendations regarding professional development.
CONCLUSIONS: The statements recommended by this taskforce delineate the activities of a critical care pharmacist and the scope of pharmacy services within the ICU. Effort should be made from all stakeholders to implement the recommendations provided, with continuous effort toward improving the delivery of care for critically ill patients.
参考来源
- Lat I, Paciullo C, Daley MJ, et al. Position Paper on Critical Care Pharmacy Services (Executive Summary): 2020 Update. Crit Care Med. 2020. PMID: 32826489. doi:10.1097/CCM.0000000000004438
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。